These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 22134540)

  • 1. A phase II study of the combination of endocrine treatment and bortezomib in patients with endocrine-resistant metastatic breast cancer.
    Trinh XB; Sas L; Van Laere SJ; Prové A; Deleu I; Rasschaert M; Van de Velde H; Vinken P; Vermeulen PB; Van Dam PA; Wojtasik A; De Mesmaeker P; Tjalma WA; Dirix LY
    Oncol Rep; 2012 Mar; 27(3):657-63. PubMed ID: 22134540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies.
    Ma C; Mandrekar SJ; Alberts SR; Croghan GA; Jatoi A; Reid JM; Hanson LJ; Bruzek L; Tan AD; Pitot HC; Erlichman C; Wright JJ; Adjei AA
    Cancer Chemother Pharmacol; 2007 Feb; 59(2):207-15. PubMed ID: 16763792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
    Gasparetto C; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Long GD; Horwitz ME; Keogh G; Chute JP; Sullivan KM; Neuwirth R; Davis PH; Sutton LM; Anderson RD; Chao NJ; Rizzieri D
    Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas.
    Maki RG; Kraft AS; Scheu K; Yamada J; Wadler S; Antonescu CR; Wright JJ; Schwartz GK
    Cancer; 2005 Apr; 103(7):1431-8. PubMed ID: 15739208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer.
    Morris MJ; Kelly WK; Slovin S; Ryan C; Eicher C; Heller G; Scher HI
    J Urol; 2007 Dec; 178(6):2378-83; discussion 2383-4. PubMed ID: 17936848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib in combination with other therapies for the treatment of multiple myeloma.
    Orlowski RZ
    J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S16-20. PubMed ID: 19791424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets.
    Su Y; Amiri KI; Horton LW; Yu Y; Ayers GD; Koehler E; Kelley MC; Puzanov I; Richmond A; Sosman JA
    Clin Cancer Res; 2010 Jan; 16(1):348-57. PubMed ID: 20028756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of bortezomib in the treatment of metastatic malignant melanoma.
    Markovic SN; Geyer SM; Dawkins F; Sharfman W; Albertini M; Maples W; Fracasso PM; Fitch T; Lorusso P; Adjei AA; Erlichman C
    Cancer; 2005 Jun; 103(12):2584-9. PubMed ID: 15887220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different dose combinations of bortezomib and dexamethasone in the treatment of relapsed or refractory myeloma: an open-label, observational, multi-center study in China.
    Yuan ZG; Jin J; Huang XJ; Li Y; Chen WM; Liu ZG; Chen XQ; Shen ZX; Hou J
    Chin Med J (Engl); 2011 Oct; 124(19):2969-74. PubMed ID: 22040537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
    Berenson JR; Yang HH; Sadler K; Jarutirasarn SG; Vescio RA; Mapes R; Purner M; Lee SP; Wilson J; Morrison B; Adams J; Schenkein D; Swift R
    J Clin Oncol; 2006 Feb; 24(6):937-44. PubMed ID: 16418495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015).
    Blaney SM; Bernstein M; Neville K; Ginsberg J; Kitchen B; Horton T; Berg SL; Krailo M; Adamson PC
    J Clin Oncol; 2004 Dec; 22(23):4804-9. PubMed ID: 15570082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC).
    Li T; Ho L; Piperdi B; Elrafei T; Camacho FJ; Rigas JR; Perez-Soler R; Gucalp R
    Lung Cancer; 2010 Apr; 68(1):89-93. PubMed ID: 19524318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose estrogen as salvage hormonal therapy for highly refractory metastatic breast cancer: a retrospective chart review.
    Mahtani RL; Stein A; Vogel CL
    Clin Ther; 2009; 31 Pt 2():2371-8. PubMed ID: 20110046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The NFkappaB pathway and endocrine-resistant breast cancer.
    Zhou Y; Eppenberger-Castori S; Eppenberger U; Benz CC
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S37-46. PubMed ID: 16113098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours.
    Cresta S; Sessa C; Catapano CV; Gallerani E; Passalacqua D; Rinaldi A; Bertoni F; Viganò L; Maur M; Capri G; Maccioni E; Tosi D; Gianni L
    Eur J Cancer; 2008 Sep; 44(13):1829-34. PubMed ID: 18640031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.
    Papandreou CN; Daliani DD; Nix D; Yang H; Madden T; Wang X; Pien CS; Millikan RE; Tu SM; Pagliaro L; Kim J; Adams J; Elliott P; Esseltine D; Petrusich A; Dieringer P; Perez C; Logothetis CJ
    J Clin Oncol; 2004 Jun; 22(11):2108-21. PubMed ID: 15169797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA.
    Morabito F; Gentile M; Ciolli S; Petrucci MT; Galimberti S; Mele G; Casulli AF; Mannina D; Piro E; Pinotti G; Palmieri S; Catalano L; Callea V; Offidani M; Musto P; Bringhen S; Baldini L; Tosi P; Di Raimondo F; Boccadoro M; Palumbo A; Cavo M
    Eur J Haematol; 2010 Mar; 84(3):223-8. PubMed ID: 19930441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of bortezomib plus dexamethasone therapy for refractory or relapsed multiple myeloma: once-weekly administration of bortezomib may reduce the incidence of gastrointestinal adverse events.
    Fukushima T; Nakamura T; Iwao H; Nakajima A; Miki M; Sato T; Sakai T; Sawaki T; Fujita Y; Tanaka M; Masaki Y; Nakajima H; Motoo Y; Umehara H
    Anticancer Res; 2011 Jun; 31(6):2297-302. PubMed ID: 21737655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors.
    Shah MH; Young D; Kindler HL; Webb I; Kleiber B; Wright J; Grever M
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6111-8. PubMed ID: 15447997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.